Loading
NAPRT (Nicotinate phosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Catalyses the first step in the biosynthesis of NAD from nicotinic acid, the ATP-dependent synthesis of beta-nicotinate D-ribonucleotide from nicotinate and 5-phospho-D-ribose 1-phosphate. Helps prevent cellular oxidative stress via its role in NAD biosynthesis.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming GNE-617.
In plain words · NAPRT (Nicotinate phosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
NAPRT (Nicotinate phosphoribosyltransferase) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Catalyses the first step in the biosynthesis of NAD from nicotinic acid, the ATP-dependent synthesis of beta-nicotinate D-ribonucleotide from nicotinate and 5-phospho-D-ribose 1-phosphate.
No product in this corpus aims at NAPRT yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA NAPRT: RNA tissue enhanced (liver 103 nTPM); high antibody staining in 5 normal tissues; highest cancer staining ovarian cancer (3 of 11 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas NAPRT tissue; Open Targets ENSG00000147813 associations
First described 2003. Earliest sequence paper UniProt cites for the protein: Huang C.-H. et al, 2003, "Identification of nicotinate phosphoribosyltransferase as a novel FHA-HIT interaction protein (FHIP)". Source.
Sources: HGNC HGNC:30450 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6XQN6 (protein name, function text, keywords and locations (REST API)); CIViC gene NAPRT (1 evidence items, 0 assertions, 1 variants; diseases: Cancer (GraphQL API, CC0))
Catalyses the first step in the biosynthesis of NAD from nicotinic acid, the ATP-dependent synthesis of beta-nicotinate D-ribonucleotide from nicotinate and 5-phospho-D-ribose 1-phosphate. Helps prevent cellular oxidative stress via its role in NAD biosynthesis. Location: Cytoplasm, cytosol (UniProt). Locus 8q24.3 (HGNC).
RNA: tissue enhanced (liver 103 nTPM), detected in many normal tissues.
Medium: Appendix, Colon, Gallbladder, Ovary, Placenta, Rectum, Salivary gland, Stomach.
Medium only: colorectal cancer, endometrial cancer, liver cancer, melanoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"NAPRT" OR ABSTRACT:"NAPRT" OR TITLE:"nicotinate phosphoribosyltransferase" OR ABSTRACT:"nicotinate phosphoribosyltransferase" OR TITLE:"Nicotinate phosphoribosyltransferase" OR ABSTRACT:"Nicotinate phosphoribosyltransferase" OR TITLE:"PP3856" OR ABSTRACT:"PP3856" OR TITLE:"NAPRT1" OR ABSTRACT:"NAPRT1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NAPRT, not a curated reading list.